Zymeworks Inc.
Company Stats
- Market Cap
- $1.9B
- as of Sep 30, 2026
- Shares Outstanding
- 71.0M
- Free Float
- 54.5%
Income Statement
- Revenue
- $106.0M
- Operating Income
- -$92.5M
- Net Income
- -$81.1M
- EBITDA
- -$88.9M
- Revenue Growth, 3Y
- -36.4%
- FCF Margin, 3Y Avg
- -112.8%
- FCF Margin, Worst Year
- -158.9%
Cash Flow
- Free Cash Flow
- -$34.5M
- FCF Yield
- -1.8%
- Owner FCF Yield
- -3.3%
Balance Sheet
- Cash & Equivalents
- $41.2M
Returns & Capital
- Share Repurchases
- $41.7M
- Buyback Yield, 3Y Avg
- 1.3%
- SBC, 3Y Avg
- $18.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $106.0M | -$34.5M | -32.6% |
| FY2024 | $76.3M | -$112.0M | -146.8% |
| FY2023 | $76.0M | -$120.8M | -158.9% |
| FY2022 | $412.5M | $136.0M | 33.0% |
| FY2021 | $26.7M | -$204.9M | -767.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 25, 2026
Deals
Zymeworks Partners ZW209 With Roche for $55 Million Upfront
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 29, 2026
Deals
Zymeworks to Buy Theravance Biopharma in $929 Million Cash Deal
Zymeworks Partners ZW209 With Roche for $55 Million Upfront
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 29, 2026
Deals
Zymeworks to Buy Theravance Biopharma in $929 Million Cash Deal